NEWS
Company news
In the News
FDA approves treatment for adults with Alzheimer’s disease
Takeda Inks Potential $2.2B Deal for AC Immune’s Alzheimer’s Immunotherapy
Summary of the Current Status of DNA Vaccination for Alzheimer Disease
Paving the way for anti-Abeta active immunotherapy
PharmaJet Partner, Institute for Molecular Medicine, Launches Clinical Trial for the First in Human Alzheimer’s DNA Vaccine
Alzheimer's vaccine is expected to enter Clinical Phase 1 in the second quarter of the U.S.
DNA vaccine spurs antibodies against a common Parkinson's target in mice
NIH's new Parkinson's disease vaccine will enter human trials
Oh, Where Vaccines Could Take Us
NOVEL PREVENTIVE VACCINE FOR PARKINSON’S DISEASE WOULD MOVE INTO HUMAN TRIALS
Novel Preventive Vaccine for Parkinson's Disease Would Move into Human Trials
Giving Thanks for Scientific Advances and COVID-19 Relief
As gene-editing moves mainstream, a pioneer in the field is testing whether it could prevent Alzheimer's
Alzheimer: passi avanti per lo sviluppo di un vaccino
New Phase 3 Data Show Positive Correlation Between ADUHELM™ Treatment Effect on Biomarkers and Reduction in Clinical Decline in Alzheimer’s Disease
Vaccine for Alzheimer’s Could Be on the Horizon
Developing a Vaccine for Alzheimer’s Disease
Nuravax Acquires Rights for MultiTEP Vaccine Platform Tech
Press Releases
Hoag's Pickup Family Neurosciences Institute Selected to Participate in Revolutionary Clinical Trial for the Prevention of Alzheimer's Disease
A novel dementia vaccine targeting three B cell epitopes of Pathological α-Synuclein
Gates Biomanufacturing Facility Announces Manufacture of Recombinant Protein - Alzheimer's Disease Vaccine for Institute for Molecular Medicine's Clinical Trials
Institute for Molecular Medicine Receives $12 Million NIH Grant to Fund Clinical Trials of AV-1959, First Preventive Vaccine for Alzheimer's Disease
Novel Preventive Vaccine for Parkinson's Disease Would Move into Human Trials
The Institute for Molecular Medicine Exclusively Licenses MultiTEP, a Universal Vaccine Platform Technology, to New Biotechnology Company Nuravax
The Institute for Molecular Medicine has Received a Total $7.7M From NIH to Develop a First-of-its-Kind Vaccine Targeting Both Hallmarks of Alzheimer's Disease